Bi
BioVersys
Basel CHFounded 200850 employees
Private CapbiotechPrivateInfectious Disease
Platform: Antibiotic Res
Market Cap
N/A
All Drugs
2
Clinical Trials
5
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sovasacituzumab | BIO-1294 | Phase 2 | 1 | TIM-3 | Endometrial CaHCC | ||
| Zorilucimab | BIO-5668 | Approved | 4 | PSMA | WMCLL |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)